MedTrace Logo

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2026-04-23

No results posted yet for this study

Summary

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Conditions

  • Atopic Dermatitis (AD)

Interventions

BIOLOGICAL

BFB759

BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis

DRUG

Placebo

Placebo for BFB759

Sponsors & Collaborators

  • Bluefin Biomedicine, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2027-02-28
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07105488 on ClinicalTrials.gov